Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511–21. https://doi.org/10.1136/annrheumdis-2021-221035.

Article  PubMed  Google Scholar 

Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23(7):383–91. https://doi.org/10.1097/rhu.0000000000000589.

Article  PubMed  PubMed Central  Google Scholar 

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34. https://doi.org/10.1136/ard-2022-223296.

Article  PubMed  Google Scholar 

Tam LS, Wei JC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, et al. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 2019;22(3):340–56. https://doi.org/10.1111/1756-185x.13510.

Article  PubMed  Google Scholar 

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–613. https://doi.org/10.1002/art.41042.

Article  PubMed  PubMed Central  Google Scholar 

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–51. https://doi.org/10.1016/s0140-6736(18)31946-9.

Article  PubMed  Google Scholar 

Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and Safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611. https://doi.org/10.1002/art.40753.

Article  PubMed  PubMed Central  Google Scholar 

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176–85. https://doi.org/10.1136/annrheumdis-2019-216118.

Article  PubMed  Google Scholar 

Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, et al. Translating improvements with ixekizumab in clinical trial outcomes into clinical practice: ASAS40, pain, fatigue, and sleep in ankylosing spondylitis. Rheumatol Ther. 2019;6(3):435–50. https://doi.org/10.1007/s40744-019-0165-3.

Article  PubMed  PubMed Central  Google Scholar 

Kiltz U, Wei JC, van der Heijde D, van den Bosch F, Walsh JA, Boonen A, et al. Ixekizumab improves functioning and health in the treatment of radiographic axial spondyloarthritis: week 52 results from 2 pivotal studies. J Rheumatol. 2021;48(2):188–97. https://doi.org/10.3899/jrheum.200093.

Article  PubMed  Google Scholar 

Deodhar AA, Mease PJ, Rahman P, Navarro-Compán V, Strand V, Hunter T, et al. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial spondyloarthritis: COAST-V/W 52-week results. BMC Rheumatol. 2021;5(1):35. https://doi.org/10.1186/s41927-021-00205-3.

Article  PubMed  PubMed Central  Google Scholar 

Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67(9):1276–81. https://doi.org/10.1136/ard.2007.073098.

Article  PubMed  Google Scholar 

Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1(1):e000017. https://doi.org/10.1136/rmdopen-2014-000017.

Article  PubMed  PubMed Central  Google Scholar 

Kong N, Hu J, Liu D, Li J, Wu H, Sun L, et al. Efficacy of ixekizumab in Chinese patients with radiographic axial spondyloarthritis by baseline C-reactive protein level. Rheumatol Ther. 2025;12:627–39. https://doi.org/10.1007/s40744-025-00765-7.

Article  PubMed  PubMed Central  Google Scholar 

Maksymowych WP, Bolce R, Gallo G, Seem E, Geneus VJ, Sandoval DM, et al. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging. Rheumatology (Oxford). 2022;61(11):4324–34. https://doi.org/10.1093/rheumatology/keac104.

Article  PubMed  Google Scholar 

Zhang S, Peng L, Li Q, Zhao J, Xu D, Zhao J, et al. Spectrum of spondyloarthritis among Chinese populations. Curr Rheumatol Rep. 2022;24(8):247–58. https://doi.org/10.1007/s11926-022-01079-1.

Article  PubMed  PubMed Central  Google Scholar 

Xue Y, Hu J, Liu D, Li J, Wu H, Tan C, et al. Ixekizumab for active radiographic axial spondyloarthritis in Chinese patients: 16- and 52-week results from a phase III, randomized, double-blind, placebo-controlled study. BioDrugs. 2024;38(1):145–56. https://doi.org/10.1007/s40259-023-00625-2.

Article  PubMed  Google Scholar 

Zhu X, Hu J, Liu D, Li J, Wu H, Sun L, et al. Rapid and sustained effect of ixekizumab on patient global, spinal pain, stiffness, and fatigue in Chinese patients with radiographic axial spondyloarthritis. Rheumatol Ther. 2024;11(4):1011–22. https://doi.org/10.1007/s40744-024-00688-9.

Article  PubMed  PubMed Central  Google Scholar 

van der Heijde D, Sieper J, Maksymowych WP, Brown MA, Lambert RG, Rathmann SS, et al. Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2014;66(3):667–73. https://doi.org/10.1002/art.38283.

Article  PubMed  PubMed Central  Google Scholar 

van den Berg R, de Hooge M, Bakker PA, van Gaalen F, Navarro-Compán V, Fagerli KM, et al. Metric properties of the SPARCC score of the sacroiliac joints—data from baseline, 3-month, and 12-month followup in the SPACE cohort. J Rheumatol. 2015;42(7):1186–93. https://doi.org/10.3899/jrheum.140806.

Article  PubMed  Google Scholar 

Mazurov VI, Dubinina TV, Erdes S, Lapshina SA, Soroka NF, Kunder EV, et al. Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study. Clin Exp Rheumatol. 2023;41(3):718–26. https://doi.org/10.55563/clinexprheumatol/ljpqqe.

Article  PubMed  Google Scholar 

Braun J, Blanco R, Marzo-Ortega H, Gensler LS, van den Bosch F, Hall S, et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021;23(1):231. https://doi.org/10.1186/s13075-021-02613-9.

Article  PubMed  PubMed Central  Google Scholar 

Richter F, Natura G, Ebbinghaus M, von Banchet GS, Hensellek S, König C, et al. Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents. Arthritis Rheum. 2012;64(12):4125–34. https://doi.org/10.1002/art.37695.

Article  PubMed  Google Scholar 

de Vlam K, Maksymowych WP, Gallo G, Rahman P, Mease P, Krishnan V, et al. Exploring the effects of ixekizumab on pain in patients with ankylosing spondylitis based on objective measures of inflammation: post hoc analysis from a large randomized clinical trial. Rheumatol Ther. 2024;11(3):691–707. https://doi.org/10.1007/s40744-024-00660-7.

Article  PubMed  PubMed Central  Google Scholar 

de Winter J, de Hooge M, van de Sande M, de Jong H, van Hoeven L, de Koning A, et al. Magnetic resonance imaging of the sacroiliac joints indicating sacroiliitis according to the assessment of SpondyloArthritis International Society definition in healthy individuals, runners, and women with postpartum back pain. Arthritis Rheumatol. 2018;70(7):1042–8. https://doi.org/10.1002/art.40475.

Article  PubMed  PubMed Central  Google Scholar 

Weber U, Jurik AG, Zejden A, Larsen E, Jørgensen SH, Rufibach K, et al. Frequency and anatomic distribution of magnetic resonance imaging features in the sacroiliac joints of young athletes: exploring “background noise” toward a data-driven definition of sacroiliitis in early spondyloarthritis. Arthritis Rheumatol. 2018;70(5):736–45. https://doi.org/10.1002/art.40429.

Article  PubMed  Google Scholar 

Varkas G, de Hooge M, Renson T, De Mits S, Carron P, Jacques P, et al. Effect of mechanical stress on magnetic resonance imaging of the sacroiliac joints: assessment of military recruits by magnetic resonance imaging study. Rheumatology (Oxford). 2018;57(3):508–13. https://doi.org/10.1093/rheumatology/kex491.

Article  PubMed